MMP2 and AL amyloidosis: Given the contribution of MMP-2 to the progression of several skeletal malignancies, we posit that the combined MMP-2 inhibition and anti-osteoclast activity of ML104 explains why ML104 and zoledronate behave similarly in vivo in preventing multiple myeloma progression.